Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Development

Combination Therapy

Tango’s PRMT5 Inhibitor Plus Daraxonrasib Shows 92% Response in Biomarker‑Selected Pancreatic Cancer

Topline phase 1/2 results suggest the MTAP‑deleted, RAS‑mutant combination could enable a precision, chemotherapy‑sparing first‑line approach if randomized trials confirm the finding.

5 ARTICLES

2mo ago

Erleada Plus Hormone Therapy Cuts Recurrence and Death in High‑Risk Localized Prostate Cancer

4 ARTICLES

2mo ago

EU Panel Recommends Braftovi Plus Cetuximab and FOLFOX for First‑Line BRAF‑Mutant Colorectal Cancer

3 ARTICLES

4mo ago

AstraZeneca’s Imfinzi–Imjudo Regimen Improves Progression-Free Survival in Liver Cancer Trial

3 ARTICLES

5mo ago

PrimeC Shows Safety and Potential Benefit in ALS Phase 2b as FDA Authorizes Phase 3

6 ARTICLES

5mo ago

Single Daily Bictegravir–Lenacapavir Pill Matches Complex HIV Regimens in Phase III

16 ARTICLES

6mo ago

Spanish Team Eradicates Pancreatic Tumors in Mice With Triple-Drug Regimen, PNAS Study Finds

9 ARTICLES

6mo ago

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

5 ARTICLES

7mo ago

AstraZeneca’s LATIFY Phase 3 Finds No Survival Benefit for Ceralasertib Plus Imfinzi in Pre-Treated NSCLC

6 ARTICLES

8mo ago

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer

3 ARTICLES

8mo ago

Gilead’s BIC/LEN HIV Tablet Matches Biktarvy in Phase 3 Switch Trial

13 ARTICLES

9mo ago

Zymeworks Shifts to Royalty Model After Ziihera’s Phase 3 Win in HER2‑Positive Gastroesophageal Cancer

5 ARTICLES

9mo ago

Padcev–Keytruda Cuts Recurrence and Death Risk in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

3 ARTICLES

10mo ago

J&J Myeloma Trial Stopped Early After Tecvayli–Darzalex Shows PFS and OS Benefit

5 ARTICLES

last yr.

Padcev and Keytruda Combo Extends Survival in Bladder Cancer Trial

5 ARTICLES

last yr.

Celcuity’s Gedatolisib Combos Yield Up to 76% Progression-Free Survival Gain in Phase 3 Trial

10 ARTICLES

last yr.

Cancer Drugs Reverse Alzheimer’s Pathology in Mice, Advance to Clinical Trials

Combination Therapy

Tango’s PRMT5 Inhibitor Plus Daraxonrasib Shows 92% Response in Biomarker‑Selected Pancreatic Cancer

Erleada Plus Hormone Therapy Cuts Recurrence and Death in High‑Risk Localized Prostate Cancer

EU Panel Recommends Braftovi Plus Cetuximab and FOLFOX for First‑Line BRAF‑Mutant Colorectal Cancer

AstraZeneca’s Imfinzi–Imjudo Regimen Improves Progression-Free Survival in Liver Cancer Trial

PrimeC Shows Safety and Potential Benefit in ALS Phase 2b as FDA Authorizes Phase 3

Single Daily Bictegravir–Lenacapavir Pill Matches Complex HIV Regimens in Phase III

Spanish Team Eradicates Pancreatic Tumors in Mice With Triple-Drug Regimen, PNAS Study Finds

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

AstraZeneca’s LATIFY Phase 3 Finds No Survival Benefit for Ceralasertib Plus Imfinzi in Pre-Treated NSCLC

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer

Never miss stories about

Combination Therapy

Gilead’s BIC/LEN HIV Tablet Matches Biktarvy in Phase 3 Switch Trial

Zymeworks Shifts to Royalty Model After Ziihera’s Phase 3 Win in HER2‑Positive Gastroesophageal Cancer

Padcev–Keytruda Cuts Recurrence and Death Risk in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

J&J Myeloma Trial Stopped Early After Tecvayli–Darzalex Shows PFS and OS Benefit

Padcev and Keytruda Combo Extends Survival in Bladder Cancer Trial

Celcuity’s Gedatolisib Combos Yield Up to 76% Progression-Free Survival Gain in Phase 3 Trial

Cancer Drugs Reverse Alzheimer’s Pathology in Mice, Advance to Clinical Trials

Never miss stories about

Combination Therapy